Caris Life Sciences, Inc. (CAI) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

97.8x

EV/EBITDA

39.1x

Market Cap

$7.08B

MomentumView details →

1D Return

−0.99%

YTD Return

−8.45%

RSI (14)

58.7

ValuationView details →

P/E (Fwd)

97.8x

EV/EBITDA

39.1x

Market Cap

$7.08B

RSI (14)

58.7

MomentumView details →

1D Return

−0.99%

YTD Return

−8.45%

ProfitabilityView details →

Gross Margin

69.66%

Net Margin

10.62%

EBITDA Margin

17.45%

ROE (TTM)

17.77%

ROA (TTM)

8.55%

Asset Turnover

0.83x

GrowthView details →

Revenue YoY

+104.87%

EPS YoY

+111.59%

FCF YoY

+186.53%

Revenue CAGR 3Y

+46.46%

EPS CAGR 3Y

+29.26%

EBITDA YoY

+168.02%

EarningsView details →

EPS (Actual)

−$0.00

EPS Surprise

−139.18%

Beats (12Q)

2/12

Next Q EPS Est

$0.03

Avg Surprise (4Q)

−566.66%

Rev Surprise

10.75%

Capital & dividendView details →

Debt/Equity

0.76x

Current Ratio

5.53x

Quick Ratio

4.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

989.61M

Net Income (TTM)

105.14M

Op. CF (TTM)

201.43M

Next earningsNov 4, 2026 →

Latest newsMore news →

Caris Life Sciences announced it will present seven studies advancing precision oncology at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.3d ago

Caris Life Sciences published a study in npj Precision Oncology describing the development and validation of its AI tool, Caris AI Insights, to guide first-line treatment choice for pancreatic cancer.8d ago

Similar companies

Rhythm Pharmaceuticals, Inc.RYTM 诺禾致源688315.SH 星湖科技600866.SH 昊海生科688366.SH Scholar Rock Holding CorporationSRRK Arcellx, Inc.ACLX Find similar companies →

Latest newsMore news →

Caris Life Sciences announced it will present seven studies advancing precision oncology at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.3d ago Caris Life Sciences published a study in npj Precision Oncology describing the development and validation of its AI tool, Caris AI Insights, to guide first-line treatment choice for pancreatic cancer.8d ago